In efforts to identify crucial cellular and molecular targets for glioma treatment, recent studies have indicated that all grades of gliomas contain putative tumor stem cells, which can be CD133+ or CD133−[5], [6]. This evidence concerns the gene PROM1 and central nervous system cancer.